Merck and Seattle Genetics have announced two strategic oncology collaborations: one to develop Seattle Genetics’ antibody-drug conjugate ladiratuzumab vedotin worldwide; and another to accelerate the global reach of Tukysa (tucatinib).
The company is delving into clinical research partnerships geared toward saving the lives of soldiers, eventually translating findings to civilian care.
The company’s Medidata Detect centralized trial monitoring solution is designed to improve management of data quality, site monitoring and patient safety.
Innovative research by Tabula Rasa Healthcare uses simulation technology to analyze potential adverse drug events of potential therapies for the virus.
